Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Strong antimicrobial activity and unique physicochemical characteristics in honey from Australian stingless bees <i>Tetragonula carbonaria</i>, <i>Tetragonula hockingsi</i>, and <i>Austroplebeia australis</i>.

Applied and environmental microbiology·2025

Same author

Optimizing Therapeutics for Intratumoral Cancer Treatments: Antiproliferative Vanadium Complexes in Glioblastoma.

International journal of molecular sciences·2025

Same author

Tetranuclear Polypyridylruthenium(II) Complexes as Selective Nucleic Acid Stains for Flow Cytometric Analysis of Monocytic and Epithelial Lung Carcinoma Large Extracellular Vesicles.

Biomolecules·2024

Same author

Fluorescent, phosphorescent, magnetic resonance contrast and radioactive tracer labelling of extracellular vesicles.

Chemical Society reviews·2024

Same author

Long-term stability and the physical and chemical factors predictive for antimicrobial activity in Australian honey.

PloS one·2024

Same author

Neutral rhenium(I) tricarbonyl complexes with sulfur-donor ligands: anti-proliferative activity and cellular localization.

Dalton transactions (Cambridge, England : 2003)·2024

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications

Published on: April 21, 2022

Recent developments in ruthenium anticancer drugs.

Aviva Levina¹, Anannya Mitra, Peter A Lay

¹School of Chemistry, The University of Sydney, Sydney NSW 2006, Australia.

Metallomics : Integrated Biometal Science

|February 10, 2011

Summary

Ruthenium (Ru) anticancer drugs show promise by interacting with biological targets like proteins and DNA. Their diverse mechanisms, including anti-metastatic and cytotoxic actions, may overcome tumor resistance.

More Related Videos

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphos^Ph Complexes

Published on: April 10, 2015

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Related Experiment Videos

Last Updated: Jun 4, 2026

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications

Published on: April 21, 2022

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphos^Ph Complexes

Published on: April 10, 2015

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Area of Science:

Medicinal Chemistry
Oncology
Biochemistry

Background:

Growing interest in Ruthenium (Ru) anticancer drugs, with NAMI-A and KP1019 completing Phase I clinical trials.
Need for critical review of literature to understand mechanisms of action for Ru-based anticancer drugs.

Purpose of the Study:

To critically review recent literature on Ru-based anticancer drugs.
To ascertain likely mechanisms of action, focusing on interactions with biological media.
To explore Ru complex interactions with plasma proteins, extracellular matrix, cell surface molecules, enzymes, and DNA.

Main Methods:

Literature review of Ru-based anticancer drug interactions with biological systems.
Analysis of metabolic pathways including reduction, aquation, hydrolysis, protein binding, and cellular diffusion.
Consideration of novel techniques like X-ray absorption spectroscopy and X-ray fluorescence microscopy for mechanistic insights.

Main Results:

Ru complexes interact with albumin and transferrin in blood plasma (depot and transport roles).
Interactions with extracellular matrix (collagens) and cell surface actins suggest anti-metastatic potential.
Ru complexes can target intracellular enzymes and DNA, and some induce free radical formation (photodynamic therapy or cellular reductants).
Metabolic pathways and drug participation determine anti-metastatic vs. cytotoxic effects.

Conclusions:

The diverse modes of action of Ru anticancer drugs enhance efficacy and reduce resistance potential.
Understanding these complex interactions is crucial for rational drug design.
Advanced techniques are needed for further mechanistic elucidation and development of improved Ru anticancer agents.